Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...

The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Pascal Soriot (pictured) topped up his basic salary of £1.8m with extras that included a bonus of £3.5m and share awards ...

Wearing a “Tech Support”-printed T-shirt, Elon Musk virtually took to the stage on the final day of the World Governments ...

Addressing key challenges in healthcare, Pascal Soriot, CEO of AstraZeneca, encouraged governments to develop policies that enable early disease diagnostics, improve accessibility, and encourage ...

AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a decade.

Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the ...

We wish them well in their future endeavours.” Pascal Soriot, commenting on Martin Mackay and Tony Zook’s departures. The full Senior Executive Team is now as follows: The appointment of ...